MacroGenics boosted by broad DART antibody deal with Boehringer
This article was originally published in Scrip
Executive Summary
In some timely good news for MacroGenics, it has entered a global alliance with Boehringer Ingelheim to discover, develop and commercialise antibody-based therapeutics based on its DART (Dual-Affinity Re-Targeting) platform.